

# Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/ED84A4E2CF3EN.html

Date: August 2021

Pages: 79

Price: US\$ 125.00 (Single User License)

ID: ED84A4E2CF3EN

# **Abstracts**

Eli Lilly and Co (LLY)

Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

#### **Highlights**

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Jul 26,2021: Taoiseach opens Ireland's largest solar farm and expansion to biotech facility

Jul 22,2021: Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis (Tadalafil) from Lilly

Jul 16,2021: Lilly partners with Banner Alzheimer's for donanemab's Phase III trial



Jul 14,2021: Lilly acquires biotech firm Protomer for \$1bn

Jul 09,2021: Lilly and Verge Genomics partner to use AI for drug development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



# **Contents**

#### **SECTION 1 - ABOUT THE COMPANY**

Eli Lilly and Co - Key Facts

Eli Lilly and Co - Key Employees

Eli Lilly and Co - Key Employee Biographies

Eli Lilly and Co - Major Products and Services

Eli Lilly and Co - History

Eli Lilly and Co - Company Statement

Eli Lilly and Co - Locations And Subsidiaries

**Head Office** 

Other Locations & Subsidiaries

Joint Venture

#### **SECTION 2 - COMPANY ANALYSIS**

Company Overview

Eli Lilly and Co - Business Description

**Product Category: Diabetes** 

Performance

Product Category: Immunology

Performance

Product Category: Neuroscience

Performance

Product Category: Oncology

Performance

Product Category: Other

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Other Foreign Countries

Performance

Geographical Segment: United States

Performance R&D Overview

\_....

Eli Lilly and Co - Corporate Strategy



Eli Lilly and Co - SWOT Analysis

SWOT Analysis - Overview

Eli Lilly and Co - Strengths

Eli Lilly and Co - Weaknesses

Eli Lilly and Co - Opportunities

Eli Lilly and Co - Threats

Eli Lilly and Co - Key Competitors

#### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

#### SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Eli Lilly and Co, Recent Deals Summary

#### **SECTION 5 – COMPANY'S RECENT DEVELOPMENTS**

Jul 26, 2021: Taoiseach opens Ireland's largest solar farm and expansion to biotech facility

Jul 16, 2021: Lilly partners with Banner Alzheimer's for donanemab's Phase III trial

Jul 09, 2021: Lilly and Verge Genomics partner to use AI for drug development

Jun 24, 2021: Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin

Jun 17, 2021: Lilly launches Think Talk Treat Migraine to help improve diagnosis and treatment of migraine

May 28, 2021: US DOJ probes Eli Lilly's Branchburg manufacturing site

May 27, 2021: Eli Lilly and Co: Received a subpoena from the U.S. Department of Justice

May 19, 2021: Lilly announces details of presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2021: Natco Pharma and Lilly sign licencing deal for baricitinib use in India



May 05, 2021: Lilly to Participate in Bank of America Securities 2021 Health Care Conference

## **SECTION 6 – APPENDIX**

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



# **List Of Tables**

#### LIST OF TABLES

Eli Lilly and Co, Key Facts

Eli Lilly and Co, Key Employees

Eli Lilly and Co, Key Employee Biographies

Eli Lilly and Co, Major Products and Services

Eli Lilly and Co, History

Eli Lilly and Co, Subsidiaries

Eli Lilly and Co, Joint Venture

Eli Lilly and Co, Key Competitors

Eli Lilly and Co, Ratios based on current share price

Eli Lilly and Co, Annual Ratios

Eli Lilly and Co, Annual Ratios (Cont...1)

Eli Lilly and Co, Annual Ratios (Cont...2)

Eli Lilly and Co, Interim Ratios

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Eli Lilly and Co, Recent Deals Summary

**Currency Codes** 

**Capital Market Ratios** 

**Equity Ratios** 

**Profitability Ratios** 

**Cost Ratios** 

Liquidity Ratios

Leverage Ratios

**Efficiency Ratios** 



# **List Of Figures**

## **LIST OF FIGURES**

Eli Lilly and Co, Performance Chart (2016 - 2020)

Eli Lilly and Co, Ratio Charts

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



#### I would like to order

Product name: Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

Product link: <a href="https://marketpublishers.com/r/ED84A4E2CF3EN.html">https://marketpublishers.com/r/ED84A4E2CF3EN.html</a>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/ED84A4E2CF3EN.html">https://marketpublishers.com/r/ED84A4E2CF3EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970